Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

AbbVie will commit "less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized ...

AbbVie stock has been beaten down recently because an $8.7 billion investment the company made in Cerevel Therapeutics in 2023 hasn't worked out as planned. This November, we learned that ...

The NHL has some of the most historic and unique logos in the entire world of sports. With the Seattle Kraken now in the fold, we can rank 32 logos around the league. There are many great logos ...

This post will discuss the top 10 famous logo designers and their iconic work. From Paul Rand's IBM logo to Michael Bierut's Mastercard. Logos are one of the most vital parts of a brand's identity. A ...

Omega Therapeutics ( (OMGA)) has shared an announcement. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with ...

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for ...